A further twist in the ongoing saga of Amarin’s litigation with Hikma over its US generic rival to the originator’s Vascepa (icosapent ethyl) capsules has seen Amarin file a fresh lawsuit claiming that the generic version induces infringement of three US Vascepa patents.
The new litigation revolves around patented cardiovascular indications which Hikma carved out of its generic label but which account for a large proportion of the brand’s sales, with only a relatively small proportion linked to the severe
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?